Diffuse Large B Cell Lymphoma Clinical Trials in Valhalla, New York

5 studies are recruiting for diffuse large b cell lymphoma in Valhalla, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

    The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Conf…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    New York Medical College ( Site 0113), Valhalla, New York
    Locations
    135 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT05139017 on ClinicalTrials.gov

  2. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

    Stage
    Phase 1
    Ages
    0 to 25
    Site
    New York Medical College ( Site 1023), Valhalla, New York
    Locations
    71 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06395103 on ClinicalTrials.gov

  3. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

    Stage
    Phase 1
    Ages
    13 to 90
    Site
    New York Medical College, Valhalla, New York
    Locations
    11 in total
    Run by
    Vironexis Biotherapeutics Inc.

    See if you can join NCT06533579 on ClinicalTrials.gov

  4. Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

    Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive…

    Stage
    Phase 1
    Ages
    12 to 70
    Site
    New York Medical Center, Valhalla, New York
    Run by
    New York Medical College

    See if you can join NCT04491370 on ClinicalTrials.gov

  5. Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

    The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relap…

    Stage
    Phase 2
    Ages
    3 to 31
    Site
    New York Medical College, Valhalla, New York
    Run by
    New York Medical College

    See if you can join NCT02393157 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.